Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 618
- Registration Number
- NCT00622700
- Locations
- 🇧🇬
Investigational Site Number 5307, Sofia, Bulgaria
🇦🇺Investigational Site Number 1405, Geelong, Australia
🇺🇸Investigational Site Number 8953, St. Petersburg, Florida, United States
Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT00622115
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
- Conditions
- Breast Neoplasms
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT00620100
- Locations
- 🇦🇹
Sanofi-Aventis, Vienna, Austria
🇵🇱Sanofi-aventis, Warsaw, Poland
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
- Conditions
- Dengue VirusDengue FeverDengue Hemorrhagic Fever
- Interventions
- Biological: Tetravalent CYD Dengue Vaccine, 4444 formulationBiological: Tetravalent CYD Dengue Vaccine , 5553 formulationBiological: Tetravalent CYD Dengue Vaccine , 5555 formulation
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 260
- Registration Number
- NCT00617344
- Locations
- 🇺🇸
Investigational Site 001, New Orleans, Louisiana, United States
🇺🇸Investigational Site 003, Springfield, Missouri, United States
🇺🇸Investigational Site 004, Hoover, Alabama, United States
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
- Conditions
- Breast Neoplasms
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5
- Registration Number
- NCT00617968
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
- Conditions
- Osteoporosis
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 248
- Registration Number
- NCT00616694
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00614250
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
🇫🇷Sanofi- Aventis Administrative Office, Paris, France
A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer
- Conditions
- Stomach Neoplasms
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT00611507
- Locations
- 🇨🇴
Sanofi-Aventis, Bogota, Colombia
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
- Conditions
- Neoplasms, Germ Cell and Embryonal
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT00611962
- Locations
- 🇫🇷
Sanofi-Aventis, Lyon, France
Endometrial Cancer - LOHP Alone and With 5FU
- Conditions
- Endometrial Cancer
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 31
- Registration Number
- NCT00612495
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France